Stool DNA screening for colorectal cancer: opportunities to improve value with next generation tests.
General adoption of the screening tests for colorectal cancer (CRC) by patients, health care professionals, medical centers, and third party payers rests on a favorable assessment of value. Reported cost-effectiveness estimates of stool DNA testing for CRC screening incorporated performance assumptions based on data from the first generation tests. Given the substantial technical advances in stool DNA testing that have occurred subsequently, estimates of value will need to be revisited. This review briefly examines the early cost-effectiveness estimates for stool DNA screening and looks ahead at how the next generation tests might improve such value estimates for CRC screening.
Kisiel
John B
JB
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Ahlquist
David A
DA
D000236:Adenoma / Q000175:diagnosis*; D000368:Aged; D015179:Colorectal Neoplasms / Q000175:diagnosis*; D003362:Cost-Benefit Analysis; D004273:DNA, Neoplasm / Q000032:analysis*; D005243:Feces / Q000737:chemistry*; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D008875:Middle Aged
D004273:DNA, Neoplasm